Ipsen S.A
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more
Ipsen S.A (IPSEF) - Total Assets
Latest total assets as of June 2025: $6.83 Billion USD
Based on the latest financial reports, Ipsen S.A (IPSEF) holds total assets worth $6.83 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ipsen S.A - Total Assets Trend (2004–2024)
This chart illustrates how Ipsen S.A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ipsen S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Ipsen S.A's total assets of $6.83 Billion consist of 31.4% current assets and 68.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.5% |
| Accounts Receivable | $697.20 Million | 10.8% |
| Inventory | $285.50 Million | 4.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.52 Billion | 39.1% |
| Goodwill | $699.50 Million | 10.9% |
Asset Composition Trend (2004–2024)
This chart illustrates how Ipsen S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ipsen S.A's current assets represent 31.4% of total assets in 2024, a decrease from 47.0% in 2004.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, up from 3.1% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 25.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 39.1% of total assets.
Ipsen S.A Competitors by Total Assets
Key competitors of Ipsen S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Ipsen S.A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Ipsen S.A generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Ipsen S.A generates $5.37 in net profit.
Ipsen S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.98 | 1.14 | 1.06 |
| Quick Ratio | 1.80 | 0.98 | 0.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.40 Billion | $ 234.60 Million | $ 76.20 Million |
Ipsen S.A - Advanced Valuation Insights
This section examines the relationship between Ipsen S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | $6.44 Billion |
| Market Capitalization | $2.93 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Ipsen S.A's assets below their book value (0.45 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ipsen S.A's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ipsen S.A (2004–2024)
The table below shows the annual total assets of Ipsen S.A from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.44 Billion | +1.84% |
| 2023-12-31 | $6.32 Billion | +12.75% |
| 2022-12-31 | $5.61 Billion | +12.01% |
| 2021-12-31 | $5.01 Billion | +15.97% |
| 2020-12-31 | $4.32 Billion | +0.24% |
| 2019-12-31 | $4.31 Billion | +27.52% |
| 2018-12-31 | $3.38 Billion | +9.94% |
| 2017-12-31 | $3.07 Billion | +26.76% |
| 2016-12-31 | $2.42 Billion | +25.05% |
| 2015-12-31 | $1.94 Billion | +13.12% |
| 2014-12-31 | $1.71 Billion | +9.45% |
| 2013-12-31 | $1.57 Billion | +0.27% |
| 2012-12-31 | $1.56 Billion | -4.43% |
| 2011-12-31 | $1.63 Billion | -2.67% |
| 2010-12-31 | $1.68 Billion | +6.43% |
| 2009-12-31 | $1.58 Billion | +0.45% |
| 2008-12-31 | $1.57 Billion | +18.66% |
| 2007-12-31 | $1.32 Billion | +8.95% |
| 2006-12-31 | $1.21 Billion | +28.83% |
| 2005-12-31 | $942.51 Million | +52.09% |
| 2004-12-31 | $619.71 Million | -- |